LSTA
LISATA THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $2.92 | $3.12 | +7% |
| Citadel Advisors re-entered | Q1 2025(8Q snapshot) | 5Q | $2.51 | $3.12 | +24% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at LISATA THERAPEUTICS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jan 13, 2026 — the most recent Form 4 on file — not from today.
- Form 40001334549-26-000003Jan 13, 2026
- Form 40002020260-26-000003Jan 13, 2026
- Form 40002055011-26-000003Jan 13, 2026
- Form 40001879231-26-000003Jan 13, 2026
- Form 40001192621-26-000004Jan 13, 2026
- Form 40001283301-26-000003Jan 13, 2026
- Form 40001741455-26-000003Jan 13, 2026
- Form 40001373585-26-000003Jan 13, 2026
- Form 40001309653-26-000004Jan 13, 2026
- Form 40002020260-25-000002Jan 13, 2025
- Form 40001879231-25-000002Jan 13, 2025
- Form 40001334549-25-000002Jan 13, 2025
- Form 40001192621-25-000002Jan 13, 2025
- Form 40001373585-25-000002Jan 13, 2025
- Form 40001283301-25-000002Jan 13, 2025
Fundamentals
XBRL · LISATA THERAPEUTICS, INC.Annual figures sourced directly from LISATA THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for LISATA THERAPEUTICS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 9, 2026
- 8-KMaterial eventJun 1, 2026
- 8-KMaterial eventMay 29, 2026
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 4, 2026
- 10-K/AAnnual report (amended)Apr 28, 2026
- 8-KMaterial eventApr 15, 2026
- 8-KMaterial eventApr 3, 2026
- 10-KAnnual reportMar 12, 2026
- 8-KMaterial eventMar 9, 2026
- 8-KMaterial eventFeb 27, 2026
- 8-KMaterial eventJan 27, 2026
- 8-KMaterial eventJan 21, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $3.17 | $3.12 | -2% |
| Citadel Advisors | Q1 2025 | Q2 2025 | $2.51 | $2.40 | -4% |
| Renaissance Technologies | Q3 2024 | open | $2.92 | $3.12 | +7% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.